Spruce Biosciences Inc (SPRB)

$51.87 -0.27 (-0.52%)
Market Cap 143.51M
Revenue (ttm) 0.00
Net Income (ttm) -38.97M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.19
Volume 30,800
Avg Vol 71,020
Day's Range N/A - N/A
Shares Out 2.75M
Stochastic %K 60%
Beta 3.11
Analysts Strong Sell
Price Target $152.17

Company Profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, includ...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 343 5986
Address:
611 Gateway Boulevard, Suite 740, South San Francisco, United States
CatHerder69
CatHerder69 Jun. 24 at 10:07 PM
$ADTX I sat on bags $SPRB for years and they were delisted to OTC in 2025 and I sold at over $360. Anything can happen.
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 22 at 10:28 PM
$MU $APGE $SPRB profits to VSEE
0 · Reply
djred
djred Jun. 18 at 5:56 PM
$SPRB Is there talks of a buyout? or is the main catalyst to watch out for in Q4 2026?
0 · Reply
parbv
parbv Jun. 18 at 1:57 PM
$SPRB Really crazy at this level. My only concern is potential competition from JCR down the road, but even they are several years behind.
0 · Reply
DARKP00L
DARKP00L Jun. 16 at 1:27 PM
$SPRB 08:32 on Jun. 16 2026 Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123 #tradeideas
1 · Reply
SuperGreenToday
SuperGreenToday Jun. 15 at 3:13 PM
$SPRB
0 · Reply
HenrikTheBandit
HenrikTheBandit Jun. 12 at 2:50 PM
$SPRB $225
0 · Reply
Rounderssss4
Rounderssss4 Jun. 12 at 2:49 PM
$SPRB buyout weekend
1 · Reply
Rounderssss4
Rounderssss4 Jun. 12 at 2:48 PM
$SPRB 👀
0 · Reply
HenrikTheBandit
HenrikTheBandit Jun. 12 at 2:22 PM
$SPRB buy out
0 · Reply
Latest News on SPRB
Spruce Biosciences appoints Agnieszka Jurecka as VP, medical affairs

2026-06-22T12:50:27.000Z - 2 days ago

Spruce Biosciences appoints Agnieszka Jurecka as VP, medical affairs

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

Jun 22, 2026, 8:00 AM EDT - 2 days ago

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

Spruce Biosciences initiated with a Buy at Guggenheim

2026-06-16T10:46:21.000Z - 8 days ago

Spruce Biosciences initiated with a Buy at Guggenheim

Spruce Biosciences names Eric Jordan VP, marketing, Tina Gullotta VP, finance

2026-06-15T12:17:18.000Z - 9 days ago

Spruce Biosciences names Eric Jordan VP, marketing, Tina Gullotta VP, finance

BBIO

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Jun 15, 2026, 8:00 AM EDT - 9 days ago

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

Spruce Biosciences initiated with a Buy at JonesResearch

2026-06-08T20:26:36.000Z - 16 days ago

Spruce Biosciences initiated with a Buy at JonesResearch

Spruce says long-term TA-ERT data presented at MPS Symposium

2026-06-08T20:11:27.000Z - 16 days ago

Spruce says long-term TA-ERT data presented at MPS Symposium

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Jun 8, 2026, 4:05 PM EDT - 16 days ago

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

Spruce Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 11:05 AM EDT - 20 days ago

Spruce Biosciences Transcript: Jefferies Global Healthcare Conference 2026

Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright

2026-06-01T10:11:46.000Z - 23 days ago

Spruce Biosciences price target lowered to $150 from $200 at H.C. Wainwright

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

May 28, 2026, 4:05 PM EDT - 27 days ago

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

Spruce Biosciences to Participate in Upcoming Conferences in June

May 27, 2026, 4:05 PM EDT - 4 weeks ago

Spruce Biosciences to Participate in Upcoming Conferences in June

Spruce Biosciences Transcript: AGM 2026

May 21, 2026, 1:00 PM EDT - 4 weeks ago

Spruce Biosciences Transcript: AGM 2026

Spruce Biosciences price target lowered to $150 from $170 at Citizens

2026-05-14T09:58:05.000Z - 6 weeks ago

Spruce Biosciences price target lowered to $150 from $170 at Citizens

Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11)

2026-05-13T16:56:50.000Z - 6 weeks ago

Spruce Biosciences reports Q1 EPS ($8.94), consensus ($6.11)

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Spruce Biosciences Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Spruce Biosciences Earnings release: Q1 2026

Spruce Biosciences Quarterly report: Q1 2026

May 13, 2026, 8:00 AM EDT - 6 weeks ago

Spruce Biosciences Quarterly report: Q1 2026

Spruce Biosciences appoints Brian Walls as VP, market access

2026-05-04T12:21:00.000Z - 7 weeks ago

Spruce Biosciences appoints Brian Walls as VP, market access

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

May 4, 2026, 8:00 AM EDT - 7 weeks ago

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy

2026-04-27T14:10:40.000Z - 2 months ago

Craig-Hallum bullish on Spruce Biosciences, initiates with a Buy

DNLI

Spruce Biosciences initiated with a Buy at Craig-Hallum

2026-04-27T12:11:23.000Z - 2 months ago

Spruce Biosciences initiated with a Buy at Craig-Hallum

Spruce Biosciences 1.15M share Spot Secondary priced at $50.00

2026-04-21T11:08:06.000Z - 2 months ago

Spruce Biosciences 1.15M share Spot Secondary priced at $50.00

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Apr 20, 2026, 11:45 PM EDT - 2 months ago

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences down 13% at $60.50 after equity offering announcement

2026-04-20T20:52:59.000Z - 2 months ago

Spruce Biosciences down 13% at $60.50 after equity offering announcement

Spruce Biosciences announces common stock offering, no amount given

2026-04-20T20:07:29.000Z - 2 months ago

Spruce Biosciences announces common stock offering, no amount given

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Apr 20, 2026, 4:01 PM EDT - 2 months ago

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Spruce Biosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Spruce Biosciences Proxy statement: Proxy filing

Spruce Biosciences Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Spruce Biosciences Proxy statement: Proxy filing

Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 12:30 PM EDT - 3 months ago

Spruce Biosciences Transcript: The Citizens Life Sciences Conference 2026

Spruce Biosciences price target lowered to $170 from $180 at Citizens

2026-03-10T09:40:19.000Z - 3 months ago

Spruce Biosciences price target lowered to $170 from $180 at Citizens

Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 11:20 AM EDT - 3 months ago

Spruce Biosciences Transcript: Leerink Global Healthcare Conference 2026

Spruce Biosciences appoints Dale Hooks as chief commercial officer

2026-03-09T11:28:43.000Z - 3 months ago

Spruce Biosciences appoints Dale Hooks as chief commercial officer

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Mar 9, 2026, 7:05 AM EDT - 3 months ago

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

Spruce Biosciences Earnings release: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Spruce Biosciences Earnings release: Q4 2025

Spruce Biosciences Annual report: Q4 2025

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Spruce Biosciences Annual report: Q4 2025

Spruce Biosciences Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 3 months ago

Spruce Biosciences Slides: Corporate presentation

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Mar 2, 2026, 4:05 PM EST - 4 months ago

Spruce Biosciences to Present at Upcoming Investor Conferences in March

Spruce Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 3:20 PM EST - 4 months ago

Spruce Biosciences Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Feb 18, 2026, 7:00 AM EST - 4 months ago

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 4:05 PM EST - 4 months ago

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Feb 5, 2026, 4:05 PM EST - 4 months ago

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Feb 3, 2026, 8:00 AM EST - 5 months ago

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Jan 28, 2026, 8:00 AM EST - 5 months ago

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Jan 18, 2026, 7:02 PM EST - 5 months ago

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Jan 8, 2026, 8:00 AM EST - 5 months ago

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Dec 15, 2025, 8:00 AM EST - 6 months ago

Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:05 PM EST - 8 months ago

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Spruce Biosciences Earnings release: Q3 2025

Spruce Biosciences Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Spruce Biosciences Quarterly report: Q3 2025

Spruce Biosciences Registration statement: Registration Filing

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Spruce Biosciences Registration statement: Registration Filing

Spruce Biosciences Registration statement: Registration Filing

Oct 29, 2025, 8:00 AM EDT - 8 months ago

Spruce Biosciences Registration statement: Registration Filing

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Oct 7, 2025, 9:44 AM EDT - 9 months ago

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Oct 6, 2025, 8:00 AM EDT - 9 months ago

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Sep 15, 2025, 7:00 AM EDT - 10 months ago

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

CatHerder69
CatHerder69 Jun. 24 at 10:07 PM
$ADTX I sat on bags $SPRB for years and they were delisted to OTC in 2025 and I sold at over $360. Anything can happen.
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 22 at 10:28 PM
$MU $APGE $SPRB profits to VSEE
0 · Reply
djred
djred Jun. 18 at 5:56 PM
$SPRB Is there talks of a buyout? or is the main catalyst to watch out for in Q4 2026?
0 · Reply
parbv
parbv Jun. 18 at 1:57 PM
$SPRB Really crazy at this level. My only concern is potential competition from JCR down the road, but even they are several years behind.
0 · Reply
DARKP00L
DARKP00L Jun. 16 at 1:27 PM
$SPRB 08:32 on Jun. 16 2026 Guggenheim Initiates Coverage On Spruce Biosciences with Buy Rating, Announces Price Target of $123 #tradeideas
1 · Reply
SuperGreenToday
SuperGreenToday Jun. 15 at 3:13 PM
$SPRB
0 · Reply
HenrikTheBandit
HenrikTheBandit Jun. 12 at 2:50 PM
$SPRB $225
0 · Reply
Rounderssss4
Rounderssss4 Jun. 12 at 2:49 PM
$SPRB buyout weekend
1 · Reply
Rounderssss4
Rounderssss4 Jun. 12 at 2:48 PM
$SPRB 👀
0 · Reply
HenrikTheBandit
HenrikTheBandit Jun. 12 at 2:22 PM
$SPRB buy out
0 · Reply
Rounderssss4
Rounderssss4 Jun. 10 at 12:37 PM
$CELC need 💯 today bring $SPRB up to 💯 too.
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 5 at 7:41 PM
$VSEE 🤔 Somethingcooking.. Up to something $COSM $OPEN $SPRB HOLD
0 · Reply
Rounderssss4
Rounderssss4 Jun. 5 at 2:47 PM
$SPRB presentation here tomorrow need to get some eyes on this again @Steve_TheBull_Rogers Martin shkreli PHARMA BRO has a 500 pt on this , awfully quiet in here stock has consolidated. Bla filing before Q4@PLATINUM_TRADES @ACInvestorBlog @MS_Tammy @SPARTANVI 🤑💯💯💯💯💯
1 · Reply
JUST_FACTSSS
JUST_FACTSSS Jun. 1 at 10:46 PM
$SPRB STABLE IN THIS ZONE FOR 6 MONTHS WILL PRESENTAIONS ON THERE (TA-ERR) for SANFILIPPO SYNDROME spark a 250.00 price hit once again PRESENTATION ON SAT 6 / 10a.m. (cest) I hate when they do them on Saturdays🤬
1 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE Jun. 1 at 10:37 PM
$VSEE don’t sleep on this one. Agreements underway with the US Department of Health and Human Services 52.76 billion expected to grow in revenue. $SPCE $SPRB $AIIO HOLD.
0 · Reply
Megabyte48
Megabyte48 Jun. 1 at 3:40 PM
$SPRB
0 · Reply
DARKP00L
DARKP00L Jun. 1 at 11:08 AM
$SPRB 07:03 on Jun. 01 2026 HC Wainwright & Co. Maintains Buy on Spruce Biosciences, Lowers Price Target to $150 #tradeideas
0 · Reply
1AMBITIOUSSAVAGE
1AMBITIOUSSAVAGE May. 28 at 10:11 PM
$VSEE $SPRB $SPRC $SPCE $NVDA
0 · Reply
Boniator305
Boniator305 May. 28 at 6:24 PM
$ASTC this is the next $SMX and $SPRB
0 · Reply
MilsLearning
MilsLearning May. 22 at 7:39 PM
$SPRB 🩳🖕🔥
0 · Reply
MilsLearning
MilsLearning May. 22 at 9:41 AM
$SPRB
0 · Reply
MilsLearning
MilsLearning May. 22 at 9:01 AM
$SPRB
0 · Reply